Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Researchers’ Doubts About Nicotine Replacement Therapy Threaten Coverage

This article was originally published in The Tan Sheet

Executive Summary

Nicotine replacement therapy sales could take a hit if health policy makers heed advice not to increase coverage for the products at the expense of other allegedly more effective interventions. A recent study found NRT is no more effective in helping people quit smoking than going cold turkey.

You may also be interested in...



E-cigarette Form Could Have Functional Edge In Cessation

E-cigarettes effectively helped smokers in a study reduce and quit smoking – even if they did not have nicotine. The “unpredicted” discovery suggests addressing the rituals of smoking play an important role in cessation and could give e-cigarettes an edge over patches, gum and lozenges.

E-cigarette Form Could Have Functional Edge In Cessation

E-cigarettes effectively helped smokers in a study reduce and quit smoking – even if they did not have nicotine. The “unpredicted” discovery suggests addressing the rituals of smoking play an important role in cessation and could give e-cigarettes an edge over patches, gum and lozenges.

Smoking Cessation Savings Outweigh Costs Of Subsidies - Study

A 1study showing that the financial benefits of government subsidies for smoking cessation programs outweigh their costs prompts advocates and researchers to urge Medicaid coverage for the products, which could boost product sales

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel